IGF1R and adrenal cortex carcinoma: However, the insulin-like growth factor 1 receptor (IGF1R) inhibitor linsitinib and immune checkpoint inhibitors such as anti-PD-1 nivolumab and pembrolizumab have not been shown to have a significant effect in ACC-related studies [8–10].